Current Funding Opportunities:

Sponsor: AFM-TéléthonDescription: This international call for proposals, open to both French and foreign groups, aims to support research which will increase our understanding of the neuromuscular system or encourage the development of therapies for neuromuscular diseases and/or rare genetic diseases. Concerning projects on ALS, priority will be given to therapeutic innovation.Deadline: Application due by April 9, 2019.

Sponsor: Hertie FoundationDescription: The prize recognizes outstanding work by young researchers in any field of neuroscience. The prize includes: € 50,000 research budget and € 50,000 for personal use. The awardee also presents "The Eric Kandel Prize Lecture" at the FENS Forum 2020 in Glasgow, United Kingdom.Deadline: Nominations due by May 1, 2019.

Sponsor: Harrington Discovery InstituteDescription: The Harrington Scholar-Innovator Award recognizes physician-scientist innovators throughout the U.S. whose research has the potential to change standard of care. The Scholar-Innovator Award provides research and drug development support to help bridge the gap between basic discovery and the clinical realm. A maximum of $700,000 USD will be awarded.Deadline: Application due by May 3, 2019.

Sponsor: Multiple Funding AgenciesDescription: The Medical Research Council (MRC) in the UK in collaboration with the National Science Foundation of the United States, Canadian Institutes of Health Research (CIHR) of Canada, Fonds de Recherche du Quebec (FRQ) of Quebec, and Deutsche Forschungsgemeinschaft (DFG) of Germany are pleased to invite proposals for NeuroNex. This initiative will provide funding for high-quality UK-based research projects focused on addressing grand challenges in neuroscience as part of larger networks with international groups.Deadline: Application due by June 14, 2019.

Sponsor: US Department of Defense CDMRPDescription: The goal of the Amyotrophic Lateral Sclerosis Research Program is to fund innovative preclinical research to promote the development of new treatments that may contribute to a cure for ALS. The program supports post-discovery, preclinical development of therapeutics for ALS. The maximum award is $1,000,000 USD, or $1,250,000 USD if applying under the Therapeutically Relevant Marker Option. Preliminary data including identity and purity of the identified bioactive compound(s) are required. Collaboration with industry is encouraged.
Deadline: Pre-Proposal due by March 22, 2019.

Sponsor: US Department of Defense CDMRPDescription: The goal of this program is to fund innovative preclinical research to promote the development of new treatments that may contribute to a cure for ALS. Funding priorities include screening methods or new ideas aimed at ALS drug or treatment discovery still in the early stages of development. A maximum of $500,000 USD will be awarded.
Deadline: Pre-Proposal due by March 22, 2019.

Sponsor: Muscular Dystrophy AssociationDescription: Clinical research grants are designed to support observational studies such as natural history, biomarker, and outcome measure studies. Clinical trials of compounds already on the market performed at academic medical centers may also be considered. Deadline: Letter of Intent due by April 1, 2019.

Sponsor: Fight MNDDescription: This Fellowship will support early-career researchers (within 5 years following award of their PhD) to lead a research project aimed at understanding the causes of MND, elucidating disease mechanisms and facilitating the translation of therapeutic strategies from the laboratory to the clinic. A total of AUD $100,000 per annum for support of a 3-year full-time Fellowship, with an overall maximum of $300,000 for a 3-year award. Proposals for both discovery and translational research stages will be considered. Applications are invited for researchers based in institutions within Australia. Applicants must have completed their PhD within 5 years at the time of application.Deadline: Application due by April 1, 2019.

Sponsor: Fight MNDDescription: IMPACT (IMProving and ACcelerating Translation) Grants support projects focused on one or more of the following key issues contributing to the lack of translation of effective treatments through to clinical trial for MND/ALS: disease heterogeneity; Lack of relevant preclinical models; a lack of reliable disease biomarkers; the challenge of drug delivery into the brain; a lack of effective targeted gene therapies; the untapped potential of stem cell therapy. These grants are for support of 2-year projects up to the value of AUD $250,000. Proposals for both discovery and translational research stages will be considered. Applications are invited for research based in institutions within Australia. Investigators at all academic levels are eligible to submit applications.
Deadline: Application due by April 1, 2019.

Sponsor: Fight MNDDescription: This Fellowship will support mid-career researchers (5 – 12 years following award of their PhD) to lead a research project aimed at understanding the causes of MND/ALS, elucidating disease mechanisms and facilitating the translation of therapeutic strategies from the laboratory to the clinic. A total of AUD $100,000 per annum for support of a 3-year full-time Fellowship, with an overall maximum of $300,000 for a 3-year award. Proposals for both discovery and translational research stages will be considered. Applications are invited for researchers based in institutions within Australia. Applicants must have completed their PhD within 5 – 12 years at the time of application.
Deadline: Application due by April 1, 2019.

Sponsor: SMA EuropeDescription: SMA Europe is pleased to announce its 10th international Call for SMA Research Projects. This new Call for SMA Projects will be open to any research project aimed at finding a therapy for Spinal Muscular Atrophy (SMA) or at elucidating the basic pathophysiological processes of the disease. Priority will, however, be given to projects concentrating on the following areas: SMN-independent mechanisms of disease, SMA as a whole-body disease, biomarkers and evidence-based standard of care and patients evaluation.Deadline: Application due by April 3, 2019.

Sponsor: NINDSDescription: This Funding Opportunity Announcement (FOA) encourages small business applications for exploratory clinical trials of investigational agents (drugs, biologics, surgical therapies or devices) that may contribute to the justification for and provide the data required for designing clinical studies. Diseases chosen for study should be based on the NINDS strategic plan and clinical research interests (www.ninds.nih.gov/funding/areas/index.htm). Deadline: Application due by April 5, 2019.

Sponsor: AFM-TéléthonDescription: This award supports clinical projects which aim to improve the management of patients, the knowledge of neuromuscular diseases and their progression, as well as the quality of life of patients affected by neuromuscular disorders.Deadline: Application due by April 9, 2019.

Sponsor: Weston Brain InstituteDescription: This program provides funding for testing of novel biomarkers in human samples, data, and/or cohorts, in order to accelerate the development of therapeutics for neurodegenerative diseases of aging. Between £300,000 – £500,000 is available per project will be awarded over up to 3 years. Deadline: Letter of Intent due by April 10, 2019.

Sponsor: Whitehall FoundationDescription: The Whitehall Foundation invites researchers to apply for their research grants. Funding priorities: basic research in neurobiology. Research grants are available to established scientists of all ages working at accredited institutions in the United States. The Foundation emphasizes the support of young scientists at the beginning of their careers and productive senior scientists who wish to move into new fields of interest. Research grants normally range from $30,000 to $75,000 per year.Deadline: Letter of Intent due by April 15, 2019.

Sponsor: Bruno and Ilse Frick Foundation for Research on ALSDescription: This aim of this award is to support early-career ALS scientists by providing funding for their basic research. Scientists across the globe are encouraged to apply! The funding is 100,000 CHF over 2 years. Deadline: Application due by September 30, 2019.

Sponsor: Motor Neurone Disease AssociationDescription: The MND Association supports biomedical research on ALS and related conditions, in all relevant disciplines. The objectives of the MND Association research funding programme are to support research aimed at understanding the causes of MND, elucidating disease mechanisms and facilitating the translation of therapeutic strategies from the laboratory to the clinic. Applications will begin to be accepted on September 6, 2019. Researchers outside the UK are eligible to apply if the project is unique in concept or design (i.e. not being performed in the UK) or the project involves a significant collaboration with a UK institute. Deadline: Application due by October 25, 2019.

Sponsor: California Institute of Regenerative Medicine (CIRM)Description: The objective of this program announcement is to create a highly competitive
partnering opportunity to accelerate the completion an IND or IDE filing with the FDA and initiate clinical trial start-up with a promising stem or progenitor cell-based treatment that addresses an unmet medical need. The maximum award is $6M USD. CIRM expects projects under this program to advance rapidly into the clinic and to achieve the proposed IND filing within 18 months.Deadline: Applications due by 2PM PST on the last business day of each month.

Sponsor: California Institute of Regenerative Medicine (CIRM)Description: The objective of this program announcement is to create a highly competitive
partnering opportunity to accelerate the completion of a clinical trial for a promising
stem or progenitor cell-based treatment that addresses an unmet medical need. The maximum award is $10-15M USD.Deadline: Applications due by 2PM PST on the last business day of each month.

Sponsor: California Institute of Regenerative Medicine (CIRM)Description: The objective of this program announcement is to support new activities on active
CIRM-funded clinical trial projects that will directly enable product registration with the
Food and Drug Administration (FDA). This award is only available to holders of a
current CLIN2 award for a trial that has been deemed by FDA to be sufficient for
registration.Deadline: Applications due by 2PM PST on the the last business day of each month.

Sponsor: Rare Diseases Models and Mechanisms NetworkDescription: On behalf of the Clinical Advisory Committee of the Rare Diseases: Models and Mechanisms Network, the Co-Chairs would like to invite applications from clinicians and clinician scientists who have discovered novel genes in patients with rare diseases and wish to collaborate with a model organism investigator who is able to carry out functional analysis on an orthologous gene in a model system. A maximum of $25,000 CAD will be awarded. Applications may be submitted by any investigator associated with a Canadian Institution. Deadline: Applications will be accepted on a rolling basis.

Sponsor: Dana FoundationDescription: This grant funds "first-in-man" clinical studies of therapies being developed for brain diseases. Funded studies can receive up to $300,000 payable over three years. Potential applicants may submit a preliminary proposal and budget to determine full proposal eligibility. Applications are not solely restricted to clinical research scientists based in the United States.Deadline: Applications are accepted on a rolling basis.

Sponsor: Weston Brain InstituteDescription: The Early Phase Clinical Trials Canada program provides funding to support clinical trials and/or clinical trial sub-studies that could accelerate the development of therapeutics for neurodegenerative disease aging, including FTD. Eligible principal investigators must be at or above the level of Assistant Professor or equivalent, and be affiliated with a CRA-qualified institution located in Canada. A maximum of $1,500,000 per project over up to 4 years. Deadline: Applications are accepted on a rolling basis.

Sponsor: Alzheimer's Drug Discovery FoundationDescription: This request for proposals supports NIA and NINDS grant proposals in NIH format that were scored but not funded, which fall within our mission and research priorities. This includes frontotemporal dementias.Deadline: Applications are accepted on a rolling basis.

Sponsor: NIH National Center for Advancing Translational Sciences (NCATS)Description: NCATS is now accepting proposals on a rolling basis to collaborate with Bridging Interventional Development Gaps (BrIDGs) and Therapeutics for Rare and Neglected Diseases (TRND) program scientists. Click here to apply.Deadline: Applications are accepted on a rolling basis.

Sponsor: NIH National Institute of Neurological Disorders and Stroke (NINDS)Description: NINDS offers a wide range of training and career development funding opportunities including pre-doctoral fellowships, post-doctoral fellowships, mentored career development awards, institutional programs, independent scientists awards, clinical research awards and more. All programs are open to researchers focusing on the study of ALS and related conditions.Deadline: Varies, see individual program for details.